Since Robles BioCeutics’ discovery that activating stem cells in the lab with toll-like receptor agonists tricks the stem cell to believe that there is tissue injury, leading to the development of its Glowselle formulation, the company has partnered with Innovigen. This manufacturing company is a California-based formulation and production manufacturer specializing in cellular and cosmetic GMP production.
Since Robles BioCeutics’ discovery that activating stem cells in the lab with toll-like receptor agonists tricks the stem cell to believe that there is tissue injury, leading to the development of its Glowselle formulation, the company has partnered with Innovigen. This manufacturing company is a California-based formulation and production manufacturer specializing in cellular and cosmetic GMP production.
In Sept. 2024, Robles filed a patent application, and in its wake, this partnership agreement marks the company’s first product, GlowSelle's, entry to the market.
The collaboration, per a July 28 press release, will focus on refining, scaling and manufacturing GlowSelle joined by Innovigen's formulation process, quality control and regulatory compliance. Under this contract, future Robles BioCeutics product lines will also undergo Innovigen's batch production, packaging and defined release criteria.
Glowselle, the company's flagship product developed in collaboration with dermatology and biotechnology clinicians, replicates an injury signal in the lab, activating the body's own stem cells to help produce essential growth factors and exosomes naturally. When isolated from "activated" stem cells, it possesses higher regenerative activity showing up to 10 times higher production of therapeutic exosomes and growth factors compared to standard adipose-derived stem cells, per a Sept. 2024 press release.
"We've been very intentional about selecting a partner who shares our commitment to innovation, transparency, and results-driven formulation," said Maria Robles, CEO and founder of Robles BioCeutics.
Under the terms of the partnership agreement, Innovigen will support joint refinement and scale-up of cosmetic formulations, including potential guidance on ingredient sourcing. Together, the companies will explore opportunities for regenerative skincare products.
